StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Consolidated revenues by Year

Consolidated revenues — Rest of World / Other International ($M) ($M)

QuarterlyAnnual

Gilead Sciences Consolidated revenues: $3,503M in FY2025, down 0.7% from a year earlier.

Latest, FY2025
3,503
Period ended Dec 31, 2025
Change on a year earlier
-0.7%
3,529 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Geographic Information.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConsolidated revenues — Rest of World / Other International ($M) ($M)Year on yearSource
FY2025Dec 31, 20253,503-0.7%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 20243,529+4.8%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20233,368-14.3%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 20223,928+24.1%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 20213,164+35.4%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 20202,337+17.3%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20191,993+7.6%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 20181,852-28.8%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 20172,602-44.3%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 20164,671–Form 10-K (filed 2019-02-26) ↗

Cite this data

StockData. (2026). Gilead Sciences Consolidated revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/geo-rev-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.